Read by QxMD icon Read

Japanese encephalitis vaccine

Yuka Saito, Meng Ling Moi, Nozomi Takeshita, Chang-Kweng Lim, Hajime Shiba, Kuniaki Hosono, Masayuki Saijo, Ichiro Kurane, Tomohiko Takasaki
BACKGROUND: Dengue virus (DENV) and Japanese encephalitis virus (JEV) belong to the genus Flavivirus, and infection with a virus within this genus induces antibodies that are cross-reactive to other flaviviruses. Particularly in DENV infection, antibodies to DENV possess two competing activities: neutralizing activity and infection-enhancing activity. These antibody activities are considered central in modulating clinical outcomes of DENV infection. Here, we determined the neutralizing and infection-enhancing activity of DENV cross-reactive antibodies in adults before and after JE vaccination...
October 18, 2016: BMC Infectious Diseases
Ziyang Sheng, Na Gao, Xiaoyun Cui, Dongying Fan, Hui Chen, Na Wu, Jianchun Wei, Jing An
Japanese encephalitis virus (JEV) is a pathogenic cause of Japanese Encephalitis (JE), which is a zoonotic disease transmitted by mosquitoes and amplified by pigs. Infection of JEV may lead to severe neurological sequelae, even death in humans and reproductive disorders in pigs. Vaccination is the only way to control JEV infection in humans. For pigs play important role in the JEV transmission cycle, developing a new veterinary vaccine is considered as a useful strategy for cutting off the transmission route of JEV...
October 12, 2016: Vaccine
K Sanchayan, R Fernandopulle, A Amarasinghe, S N Thiyahiny, S Sri Ranganathan
OBJECTIVES: This study was designed to describe the safety profile of the single dose live attenuated Japanese encephalitis vaccine (LJEV) SA-14-14-2 given at the age of 9 months in the National Immunisation programme of Sri Lanka. METHODS: cohort event monitoring (CEM) was conducted in the Jaffna district during November 2012 to January 2015. A representative sample of 3041 infants who received the LJEV at the age of 9 months was followed up actively over telephone interviews on days 1, 3, 14, 30 and 45 for adverse events (AE)...
2016: Ceylon Medical Journal
Aleš Chrdle, Vaclav Chmelik, Daniel Ruzek
Tick-borne encephalitis (TBE) is an acute febrile illness with neurological manifestations that is prevalent in forested areas of moderate climate in Europe and Asia. TBE virus is transmitted by ticks and rarely by unpasteurized milk and dairy products. The disease burden is attributed mainly to resulting long-term disability, especially in individuals over 50 years of age. Currently, there is no causative treatment, but a very effective vaccination is available with a good safety profile. The vaccination requires three basic doses to be fully effective and regular boosters afterwards...
August 15, 2016: Human Vaccines & Immunotherapeutics
A De, K Maity, Soovoojeet Jana, M Maiti
Japanese encephalitis (JE) is a public health problem that threats the entire world today. Japanese Encephalitis virus (JEV) mostly became a threat due to the significant number of increase of susceptible mosquito vectors and vertebrate hosts in Asia by which around 70,000 cases and 10,000 deaths per year took place in children below 15 years of age. In this paper, a mathematical model of JE due to JEV from the vector source (infected mosquito) and two vertebrate hosts (infected human and infected pig) is formulated...
October 1, 2016: Mathematical Biosciences
Xinjiang Lin, Xijin Xu, Xiang Zeng, Long Xu, Zhijun Zeng, Xia Huo
We explored acquired immunity resulting from vaccination in 3 to 7-year-old children, chronically exposed to multiple heavy metals and metalloids, in an e-waste recycling area (Guiyu, China). Child blood levels of ten heavy metals and metalloids, including lead (Pb), arsenic (As), mercury (Hg), chromium (Cr), cadmium (Cd), manganese (Mn), nickel (Ni), copper (Cu), zinc (Zn) and selenium (Se), and seven vaccine antibodies (diphtheria, pertussis, tetanus, hepatitis B, Japanese encephalitis, polio, measles) were measured...
September 29, 2016: Environmental Pollution
Kulkanya Chokephaibulkit, Chukiat Sirivichayakul, Usa Thisyakorn, Chitsanu Pancharoen, Mark Boaz, Alain Bouckenooghe, Emmanuel Feroldi
BACKGROUND: A single dose of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) was shown to be immunogenic and well tolerated when given either as a booster to formalin-inactivated Japanese encephalitis (JE)-vaccine (mouse brain-derived vaccine [MBDV])-primed 2-5-year-olds, or as a primary vaccination to JE-vaccine-naïve 12-24-month-old toddlers in Thailand. A 5-year follow-up assessment of immune response persistence over time was conducted. METHODS: Four additional visits (at 2, 3, 4, and 5years) for immunologic assessments were added to the original 12-month open-label crossover study, in which 100 healthy children aged 2-5years with a history of two-dose primary vaccination with MBDV (according to the Thai Expanded Program for Immunization schedule), and 200 healthy JE-vaccine-naïve 12-24-month-old toddlers, were randomized 1:1 to receive JE-CV, containing ⩾4 log10 plaque forming units, 1month before or after hepatitis A control vaccine...
September 26, 2016: Vaccine
Jin'e Fang, Huan Li, Dexin Kong, Shengbo Cao, Guiqing Peng, Rui Zhou, Huanchun Chen, Yunfeng Song
Japanese encephalitis virus (JEV) is a flavivirus that threatens more than half of the world's population. Vaccination can prevent the disease, but no specific antiviral drug is yet available for clinical therapy, and the death rate caused by JEV can reach as high as 60%. The C-terminus of non-structural protein 3 (NS3) of flavivirus encodes helicase and has been identified as a potential drug target. In this study, high throughput molecular docking was employed to identify candidate JEV NS3 helicase inhibitors in a commercial library containing 250,000 compounds...
September 29, 2016: Scientific Reports
Kuan Rong Chan, Xiaohui Wang, Wilfried A A Saron, Esther Shuyi Gan, Hwee Cheng Tan, Darren Z L Mok, Summer Li-Xin Zhang, Yie Hou Lee, Cui Liang, Limin Wijaya, Sujoy Ghosh, Yin Bun Cheung, Steven R Tannenbaum, Soman N Abraham, Ashley L St John, Jenny G H Low, Eng Eong Ooi
Vaccination has achieved remarkable successes in the control of childhood viral diseases. To control emerging infections, however, vaccines will need to be delivered to older individuals who, unlike infants, probably have had prior infection or vaccination with related viruses and thus have cross-reactive antibodies against the vaccines. Whether and how these cross-reactive antibodies impact live attenuated vaccination efficacy is unclear. Using an open-label randomized trial design, we show that subjects with a specific range of cross-reactive antibody titres from a prior inactivated Japanese encephalitis vaccination enhanced yellow fever (YF) immunogenicity upon YF vaccination...
2016: Nature Microbiology
N B Cleton, K van Maanen, S A Bergervoet, N Bon, C Beck, G-J Godeke, S Lecollinet, R Bowen, D Lelli, N Nowotny, M P G Koopmans, C B E M Reusken
The genus Flavivirus in the family Flaviviridae includes some of the most important examples of emerging zoonotic arboviruses that are rapidly spreading across the globe. Japanese encephalitis virus (JEV), West Nile virus (WNV), St. Louis encephalitis virus (SLEV) and Usutu virus (USUV) are mosquito-borne members of the JEV serological group. Although most infections in humans are asymptomatic or present with mild flu-like symptoms, clinical manifestations of JEV, WNV, SLEV, USUV and tick-borne encephalitis virus (TBEV) can include severe neurological disease and death...
September 15, 2016: Transboundary and Emerging Diseases
Pakpoom Janewongwirot, Thanyawee Puthanakit, Suvaporn Anugulruengkitt, Watsamon Jantarabenjakul, Chayapa Phasomsap, Sompong Chumket, Sutee Yoksan, Chitsanu Pancharoen
BACKGROUND: Japanese Encephalitis chimeric virus vaccine (JE-CV) and SA14-14-2 vaccine are live-attenuated JE vaccines produced from the same virus strain. Data on interchangeability is limited. OBJECTIVES: To evaluate the immunogenicity and safety of JE-CV booster after primary vaccination with SA14-14-2 vaccine. METHODS: This study was an open-label clinical trial in Thai children who had received a primary SA14-14-2 vaccination at 12-24monthsbefore enrollment (ClinicalTrials...
October 17, 2016: Vaccine
Jiang-Nan Wu, Da-Jin Li, Yong Zhou
BACKGROUND: Little is known about the association between the initiation of hepatitis B vaccine (HB vaccine) at birth and completion of the HB vaccine and the national immunization program vaccine (NIPV) series in Fujian, China. METHODS: A provincial survey, including children in the community and newborns in hospital, was conducted to evaluate coverage with a timely first dose of HB vaccine and the completion of three doses of HB vaccine and the NIPV series in 2013...
August 31, 2016: International Journal of Infectious Diseases: IJID
Kyoko Itoh, Kazuhide Iwamoto, Yu Satoh, Tomoaki Fujita, Kenta Takahashi, Harutaka Katano, Hideki Hasegawa, Tomohiko Takasaki, So Tando, Shinji Fushiki
The nationwide introduction of a Japanese encephalitis (JE) vaccine has contributed to a reduction in the annual infection rate of JE in Japan. However, the current neutralizing antibody prevalence ratio in Japan is approximately 20% in children 3-4 years of age and in people in their forties and fifties. We herein report a man with JE who was definitively diagnosed by multi-virus real-time polymerase chain reaction employing biopsied brain tissue and serological examinations. JE should be kept in mind when a patient has severe encephalitis of unknown etiology...
2016: Internal Medicine
Rosemary M Olivero, Davidson H Hamer, William B MacLeod, Christine M Benoit, Carolina Sanchez-Vegas, Emily S Jentes, Lin H Chen, Mary E Wilson, Nina Marano, Emad A Yanni, Winnie W Ooi, Adolf W Karchmer, Laura Kogelman, Elizabeth D Barnett
We conducted a prospective study to measure dengue virus (DENV) antibody seroconversion in travelers to dengue-endemic areas. Travelers seen in the Boston Area Travel Medicine Network planning to visit dengue-endemic countries for ≥ 2 weeks were enrolled from 2009 to 2010. Pre- and post-travel blood samples and questionnaires were collected. Post-travel sera were tested for anti-DENV IgG by indirect IgG enzyme-linked immunosorbent assay (ELISA) and anti-DENV IgM by capture IgM ELISA. Participants with positive post-travel anti-DENV IgG or IgM were tested for pre-travel anti-DENV IgG and IgM; they were excluded from the seroconversion calculation if either pre-travel anti-DENV IgG or IgM were positive...
August 29, 2016: American Journal of Tropical Medicine and Hygiene
Guruprasad R Medigeshi, Rinki Kumar, Ekta Dhamija, Tanvi Agrawal, Meenakshi Kar
Around 10,000 people die each year due to severe dengue disease and two-thirds of the world population lives in dengue endemic region. There has been remarkable progress in dengue vaccine development, however, there are no licensed antivirals for dengue disease and none appear to be in the clinical trials. We took the approach of repositioning approved drugs for anti-dengue activity by screening a library of pharmacologically active compounds. We identified N-Desmethylclozapine, Fluoxetine hydrochloride and Salmeterol xinafoate as dengue inhibitors based on reduction in the number of infected cells and viral titers...
August 29, 2016: Antimicrobial Agents and Chemotherapy
Su-Hua Huang, Jin-Cherng Lien, Chao-Jung Chen, Yu-Ching Liu, Ching-Ying Wang, Chia-Fong Ping, Yu-Fong Lin, An-Cheng Huang, Cheng-Wen Lin
Japanese encephalitis virus (JEV), a mosquito-borne flavivirus, has five genotypes (I, II, III, IV, and V). JEV genotype I circulates widely in some Asian countries. However, current JEV vaccines based on genotype III strains show low neutralizing capacities against genotype I variants. In addition, JE has no specific treatment, except a few supportive treatments. Compound CW-33, an intermediate synthesized derivative of furoquinolines, was investigated for its antiviral activities against JEV in this study...
2016: International Journal of Molecular Sciences
Jin-Ren Pan, Ju-Ying Yan, Jia-Yue Zhou, Xue-Wen Tang, Han-Qing He, Rong-Hui Xie, Hai-Yan Mao, Yan-Jun Zhang, Shu-Yun Xie
BACKGROUND: Sporadic Japanese encephalitis (JE) cases still have been reported in Zhejiang Province in recent years, and concerns about vaccine cross-protection and population-level immunity have been raised off and on within the public health sphere. Genotype I (GI) has replaced GIII as the dominant genotype in Asian countries during the past few decades, which caused considerable concerns about the potential change of epidemiology characteristics and the vaccine effectiveness. The aim of this study was to investigate the prevalence of JE neutralizing antibody and its waning antibody trend after live attenuated JE vaccine immunization...
August 2016: PLoS Neglected Tropical Diseases
Sang-Im Yun, Byung-Hak Song, Irina A Polejaeva, Christopher J Davies, Kenneth L White, Young-Min Lee
Japanese encephalitis virus (JEV) is the main cause of acute viral encephalitis, primarily affecting children and young adults in the Asia-Pacific region. JEV is a vaccine-preventable pathogen, with four types of JE vaccine licensed in different regions of the world. To date, the most common JEV strain used in vaccine development and production is SA14-14-2, an attenuated strain derived from its wild-type parental strain SA14. In this study, we directly compared the phenotypic and genotypic characteristics of SA14 and SA14-14-2 to determine the biological and genetic properties associated with their differential virulence...
August 5, 2016: Journal of General Virology
Byung-Chul Kim, Do-Keun Kim, Hyung-Jin Kim, Seung-Hwa Hong, Yeonhee Kim, Jong-Mi Lim, JiYoung Hong, Cheol-Hee Kim, Yong-Keun Park, Jaeok Kim
The use of inactivated Japanese encephalitis (JE) vaccines has been ongoing in East Asia for 40 years. A mouse immunogenicity assay followed by a Plaque Reduction Neutralization (PRN) Test (PRNTest) is currently recommended for each lot release of the vaccine by many national authorities. We developed an alternative in vitro ELISA to determine the E antigen content of the Japanese encephalitis virus to observe the 3Rs strategy. A collaborative study for replacing the in vivo potency assay for the Japanese encephalitis vaccine with the in vitro ELISA assay was confirmed comparability between these two methods...
September 2, 2016: Virus Research
Aftab Alam, Shahnwaz Ali, Shahzaib Ahamad, Md Zubbair Malik, Romana Ishrat
Recently, Zika virus has emerged as a potential threat to human health worldwide. Zika is the member of Flaviviridae, is transmitted to humans by mosquitoes. It is related to other pathogenic vector borne flaviviruses including dengue, West-Nile and Japanese encephalitis viruses, but produces a comparatively mild disease in humans. Despite of its epidemic outbreak and lack of potential medication, there is a need for improved vaccine /drugs. The use of computational technique will bring some facts into the research limelight...
August 3, 2016: Immunology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"